DV
Dividend Vision

BTMD — biote Corp

biote Corp (BTMD)

Total return is -85.4% over the past 5.3 years, 185.1 points behind SPY at 99.7%. Its deepest 1-year drawdown was 62.8%.

biote Corp operates a practice-building business in the hormone optimization space, providing training, certification, and software platforms to physicians and nurse practitioners who offer bioidentical hormone replacement pellet therapy. The company generates revenue through its Biote Method platform (which includes education, training, and practice management software), sales of dietary supplements and sterile pellet insertion kits, and digital marketing support services. The company does not currently distribute dividends and is oriented toward growth rather than income generation.

BTMD key facts

Asset type
Stock
Asset class
Equity
Inception date
04/28/2021
Last close
$1.47
Market cap
$86,393,984
Average volume
110800.0
Beta
1.661
Payout ratio
0.0
P/E ratio
5.6512
Forward P/E
6.7659
EPS
$0.43